Fulvestaciclib Combined With Anti-HER2 and Endocrine Therapy for HR+/HER2+ Advanced Breast Cancer (FACET)
Efficacy and Safety of Fulvestaciclib Combined With Anti-HER2 and Endocrine Therapy for First-line Maintenance or Upfront Chemo-Free Treatment in HR+/HER2+ Advanced Breast Cancer: A Multicenter, Open-label, Randomized Controlled Phase II Study
This phase II, multicenter, open-label, randomized controlled trial (FACET study) evaluates the efficacy and safety of fulvestaciclib, a novel oral CDK4/6 inhibitor, combined with anti-HER2 dual blockade (trastuzumab and pertuzumab, HP) and endocrine therapy (ET) in hormone receptor-positive (HR+) and HER2-positive advanced breast cancer (ABC).
Patients with HR+/HER2+ ABC without prior systemic therapy for advanced disease are randomized in a 1:1:1 ratio into three arms, stratified by visceral metastasis status (yes vs. no) and metastatic type (de novo vs. recurrent).
Arm A: After 4-8 cycles of induction chemotherapy (taxane) plus HP, patients receive fulvestaciclib + HP + ET as maintenance therapy.
Arm B: After 4-8 cycles of induction chemotherapy (taxane) plus HP, patients receive HP + ET alone (without fulvestaciclib) as maintenance therapy.
Arm C (exploratory): Patients receive upfront fulvestaciclib + HP + ET as first-line therapy without induction chemotherapy (chemo-free).
For premenopausal/perimenopausal patients, ovarian function suppression (OFS) is added in all arms. Treatment continues until disease progression, unacceptable toxicity, withdrawal of consent, or death.
The primary endpoint is investigator-assessed progression-free survival (PFS) comparing Arm A versus Arm B. Secondary endpoints include PFS (Arm A vs. Arm C), overall survival (OS), objective response rate (ORR), clinical benefit rate (CBR), duration of response (DoR), cumulative incidence of central nervous system (CNS) metastases, safety, and patient-reported outcomes (PROs).
調査の概要
状態
研究の種類
入学 (推定)
段階
- フェーズ2
連絡先と場所
研究連絡先
- 名前:Jian Zhang, MD
- 電話番号:+86 18017312991
- メール:syner2000@163.com
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
説明
Inclusion Criteria:
- Age ≥ 18 years, with inoperable locally advanced or recurrent/metastatic breast cancer not amenable to curative-intent therapy.
- Histologically or cytologically confirmed hormone receptor-positive (HR+) and HER2-positive (HER2+) breast cancer. HR+ is defined as estrogen receptor (ER) and/or progesterone receptor (PR) positivity with ≥1% of invasive tumor cells positive by immunohistochemistry (IHC). HER2+ is defined as IHC 3+ or IHC 2+ with in situ hybridization (ISH) positivity.
- No prior systemic therapy for advanced breast cancer, including endocrine therapy, chemotherapy, anti-HER2 therapy, or any CDK4/6 inhibitor.
- Patients may have received neoadjuvant or adjuvant therapy. If prior endocrine therapy was received in the neoadjuvant/adjuvant setting, the disease-free interval from completion of endocrine therapy to randomization must be ≥12 months. If prior anti-HER2 therapy was received, the disease-free interval from completion of anti-HER2 therapy to randomization must be ≥6 months.
- Patients with stable central nervous system (CNS) metastases (meeting all the following criteria: no disease progression on screening imaging after local therapy; at least 3 weeks from completion of local CNS therapy to Cycle 1 Day 1; no requirement for medication to control symptoms) or asymptomatic CNS metastases are eligible.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
- Any menopausal status. Postmenopausal status is defined as: a. bilateral oophorectomy; b. age ≥60 years; c. age <60 years with amenorrhea for >1 year in the absence of chemotherapy, tamoxifen, toremifene, or ovarian function suppression, and with serum FSH and estradiol levels within the postmenopausal range. For patients <60 years on tamoxifen or toremifene with amenorrhea, serum FSH and estradiol levels must be within the postmenopausal range on consecutive measurements.
- At least one evaluable lesion per RECIST 1.1 (measurable and/or non-measurable lesion).
- For women of childbearing potential: negative serum or urine pregnancy test within 7 days prior to randomization, and agreement to use adequate contraception during study treatment and for 6 months after the last dose of fulvestaciclib.
- Voluntarily sign the informed consent form (ICF), understand the study, and be willing to comply with all study procedures and follow-up.
- Adequate bone marrow and organ function defined as:
Absolute neutrophil count (ANC) ≥1.5 × 10⁹/L; Hemoglobin ≥90 g/L (no red blood cell transfusion within 14 days prior to randomization); Platelet count ≥75 × 10⁹/L; Serum total bilirubin ≤1.5 × upper limit of normal (ULN); AST and ALT ≤3 × ULN (or ≤5 × ULN in the presence of liver metastases); Serum creatinine ≤1 × ULN or calculated creatinine clearance >50 mL/min (Cockcroft-Gault formula); Baseline left ventricular ejection fraction (LVEF) ≥50%.
Exclusion Criteria:
- Inflammatory breast cancer.
- Leptomeningeal disease.
- Active brain metastases (patients with asymptomatic brain metastases, or clinically stable and not requiring steroids or other CNS-directed therapy for ≥4 weeks are eligible).
- Diagnosis of any other malignancy, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the cervix that has been definitively treated.
- Known severe hypersensitivity to any component of the study drugs.
- Myocardial infarction within 6 months prior to first dose; uncontrolled cardiac arrhythmias (QTc interval ≥470 ms by Fridericia's formula); New York Heart Association (NYHA) Class III-IV cardiac insufficiency; LVEF <50% on echocardiography; or clinically significant pleural effusion, pericardial effusion, or ascites requiring intervention.
- Dysphagia, active gastrointestinal disease, major gastrointestinal surgery, malabsorption syndrome, or any other condition that may interfere with the absorption of study drugs.
- Known active infection, including hepatitis B (HBsAg positive with HBV DNA ≥1×10⁴ copies/mL or ≥2000 IU/mL), hepatitis C, syphilis, or human immunodeficiency virus (HIV) infection.
- Major surgery, radiotherapy, tumor immunotherapy, monoclonal antibody therapy, or other systemic antitumor therapy within 30 days prior to the first dose, or any therapy that the investigator considers may interfere with the efficacy of study drugs.
- Concurrent use of other investigational drugs or therapies.
- Planned or prior organ or bone marrow transplantation.
- Known history of substance abuse or drug addiction.
- Any other condition that, in the investigator's judgment, makes the patient unsuitable for participation in this study.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Fulvestaciclib + HP + ET Maintenance
After 4-8 cycles of induction chemotherapy (taxane) plus trastuzumab and pertuzumab (HP), participants receive maintenance therapy with oral fulvestaciclib 200 mg daily (21 days on, 7 days off, 28-day cycle), HP (trastuzumab 8 mg/kg loading then 6 mg/kg IV Q3W; pertuzumab 840 mg loading then 420 mg IV Q3W), and endocrine therapy (ET: fulvestrant 500 mg IM on Days 1,15,29 then monthly, or letrozole 2.5 mg or anastrozole 1 mg PO daily).
Premenopausal/perimenopausal patients also receive ovarian function suppression (OFS).
Treatment continues until disease progression, unacceptable toxicity, withdrawal of consent, or death.
|
フルベストラント
Oral CDK4/6 inhibitor, 200 mg once daily, 21 days on/7 days off per 28-day cycle.
他の名前:
Anti-HER2 monoclonal antibody, 8 mg/kg loading dose then 6 mg/kg IV every 21 days.
Anti-HER2 monoclonal antibody, 840 mg loading dose then 420 mg IV every 21 days.
Aromatase inhibitor, 2.5 mg orally once daily.
Aromatase inhibitor, 1 mg orally once daily.
Induction chemotherapy (paclitaxel, docetaxel, or nab-paclitaxel) plus HP for 4-8 cycles prior to maintenance therapy.
|
|
アクティブコンパレータ:HP + ET Maintenance (Control)
After 4-8 cycles of induction chemotherapy (taxane) plus trastuzumab and pertuzumab (HP), participants receive maintenance therapy with HP (trastuzumab 8 mg/kg loading then 6 mg/kg IV Q3W; pertuzumab 840 mg loading then 420 mg IV Q3W) and endocrine therapy (ET: fulvestrant 500 mg IM on Days 1,15,29 then monthly, or letrozole 2.5 mg or anastrozole 1 mg PO daily) without fulvestaciclib.
Premenopausal/perimenopausal patients also receive ovarian function suppression (OFS).
Treatment continues until disease progression, unacceptable toxicity, withdrawal of consent, or death.
|
フルベストラント
Anti-HER2 monoclonal antibody, 8 mg/kg loading dose then 6 mg/kg IV every 21 days.
Anti-HER2 monoclonal antibody, 840 mg loading dose then 420 mg IV every 21 days.
Aromatase inhibitor, 2.5 mg orally once daily.
Aromatase inhibitor, 1 mg orally once daily.
Induction chemotherapy (paclitaxel, docetaxel, or nab-paclitaxel) plus HP for 4-8 cycles prior to maintenance therapy.
|
|
実験的:Upfront Fulvestaciclib + HP + ET (Chemo-free)
Participants receive first-line therapy with oral fulvestaciclib 200 mg daily (21 days on, 7 days off, 28-day cycle), HP (trastuzumab 8 mg/kg loading then 6 mg/kg IV Q3W; pertuzumab 840 mg loading then 420 mg IV Q3W), and endocrine therapy (ET: fulvestrant 500 mg IM on Days 1,15,29 then monthly, or letrozole 2.5 mg or anastrozole 1 mg PO daily) without induction chemotherapy.
Premenopausal/perimenopausal patients also receive ovarian function suppression (OFS).
Treatment continues until disease progression, unacceptable toxicity, withdrawal of consent, or death.
|
フルベストラント
Oral CDK4/6 inhibitor, 200 mg once daily, 21 days on/7 days off per 28-day cycle.
他の名前:
Anti-HER2 monoclonal antibody, 8 mg/kg loading dose then 6 mg/kg IV every 21 days.
Anti-HER2 monoclonal antibody, 840 mg loading dose then 420 mg IV every 21 days.
Aromatase inhibitor, 2.5 mg orally once daily.
Aromatase inhibitor, 1 mg orally once daily.
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Progression-Free Survival (PFS) Assessed by Investigator
時間枠:From randomization to first documented progression per RECIST 1.1 or death, assessed every 6 weeks for 12 weeks then every 12 weeks until progression, up to 6 years.
|
PFS is defined as the time from randomization to the first documented disease progression according to RECIST 1.1 criteria as assessed by the investigator, or death from any cause, whichever occurs first.
|
From randomization to first documented progression per RECIST 1.1 or death, assessed every 6 weeks for 12 weeks then every 12 weeks until progression, up to 6 years.
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Progression-Free Survival (PFS) Assessed by Investigator (Arm A vs Arm C)
時間枠:From randomization to first documented progression per RECIST 1.1 or death, assessed every 6 weeks for 12 weeks then every 12 weeks until progression, up to 6 years.
|
PFS is defined as the time from randomization to the first documented disease progression according to RECIST 1.1 criteria as assessed by the investigator, or death from any cause, whichever occurs first.
Comparison between Arm A (fulvestaciclib + HP + ET maintenance) and Arm C (upfront fulvestaciclib + HP + ET chemo-free).
|
From randomization to first documented progression per RECIST 1.1 or death, assessed every 6 weeks for 12 weeks then every 12 weeks until progression, up to 6 years.
|
|
Overall Survival (OS)
時間枠:From date of randomization to date of death from any cause, assessed up to approximately 6 years.
|
OS is defined as the time from randomization to death from any cause.
|
From date of randomization to date of death from any cause, assessed up to approximately 6 years.
|
|
Objective Response Rate (ORR)
時間枠:From randomization to progression or start of subsequent therapy, assessed every 6 weeks for 12 weeks then every 12 weeks, up to 6 years.
|
ORR is defined as the proportion of patients with a best overall response of complete response (CR) or partial response (PR) per RECIST 1.1 criteria as assessed by the investigator.
|
From randomization to progression or start of subsequent therapy, assessed every 6 weeks for 12 weeks then every 12 weeks, up to 6 years.
|
|
Clinical Benefit Rate (CBR)
時間枠:From randomization to progression or start of subsequent therapy, assessed every 6 weeks for 12 weeks then every 12 weeks, up to 6 years.
|
CBR is defined as the proportion of patients with a best overall response of CR, PR, or stable disease lasting at least 24 weeks per RECIST 1.1 criteria as assessed by the investigator.
|
From randomization to progression or start of subsequent therapy, assessed every 6 weeks for 12 weeks then every 12 weeks, up to 6 years.
|
|
Duration of Response (DoR)
時間枠:From first documented CR or PR to first progression per RECIST 1.1 or death, assessed up to 6 years.
|
DoR is defined as the time from the first documented response (CR or PR) to the first documented disease progression per RECIST 1.1 criteria as assessed by the investigator, or death from any cause, whichever occurs first.
|
From first documented CR or PR to first progression per RECIST 1.1 or death, assessed up to 6 years.
|
|
Cumulative Incidence of Central Nervous System (CNS) Metastases
時間枠:From date of randomization to date of first documented CNS metastasis, assessed up to approximately 6 years.
|
Cumulative incidence of CNS metastases will be estimated using the competing risk model (Gray's method), with death as a competing risk event.
|
From date of randomization to date of first documented CNS metastasis, assessed up to approximately 6 years.
|
|
Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) as Assessed by NCI-CTCAE v5.0
時間枠:From informed consent through 28 days after last dose; labs/ECGs every 3 weeks, echocardiograms every 12 weeks, up to 6 years.
|
Safety and tolerability will be assessed by the incidence, severity, and causality of AEs and SAEs graded according to NCI-CTCAE v5.0, as well as changes in vital signs, 12-lead ECGs, echocardiograms, and clinical laboratory parameters.
|
From informed consent through 28 days after last dose; labs/ECGs every 3 weeks, echocardiograms every 12 weeks, up to 6 years.
|
|
Patient-Reported Outcomes (PROs) Assessed by the Functional Assessment of Cancer Therapy - Breast (FACT-B) Questionnaire
時間枠:Measured at Cycle 1 Day 1 (each cycle is 28 days), every 12 weeks thereafter, and at treatment discontinuation and safety follow-up, up to 6 years.
|
Health-related quality of life assessed using FACT-B, a 36-item scale across 5 domains: physical, social/family, emotional, functional well-being, and breast cancer-specific concerns.
Total scores range from 0 to 148, with higher scores indicating better quality of life.
|
Measured at Cycle 1 Day 1 (each cycle is 28 days), every 12 weeks thereafter, and at treatment discontinuation and safety follow-up, up to 6 years.
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
- 部位別新生物
- 新生物
- 皮膚疾患
- 乳房の病気
- 皮膚および結合組織疾患
- 乳房腫瘍
- ホルモン
- ホルモン、ホルモン代替品、ホルモン拮抗薬
- アミノ酸、ペプチド、およびタンパク質
- タンパク質
- 有機化学物質
- 複素環化化合物、1リング
- 複素環化化合物
- アゾール
- 多環式化合物
- 抗体、モノクローナル、ヒト化
- 抗体、モノクローナル
- 抗体
- 免疫グロブリン
- 免疫タンパク質
- 血液タンパク質
- 血清グロブリン
- グロブリン
- ステロイド
- 融合リング化合物
- ニトリル
- エストラジオール
- Estrenes
- エストラン
- エストラジオール同族体
- ゴナダルステロイドホルモン
- ゴナダルホルモン
- トリアゾール
- トラスツズマブ
- レトロゾール
- フルベストラント
- アナストロゾール
- ペルズマブ
- タキャン
その他の研究ID番号
- HLX902-IIT-MA-BC02
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。